KR20170062781A - Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function - Google Patents
Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function Download PDFInfo
- Publication number
- KR20170062781A KR20170062781A KR1020150168378A KR20150168378A KR20170062781A KR 20170062781 A KR20170062781 A KR 20170062781A KR 1020150168378 A KR1020150168378 A KR 1020150168378A KR 20150168378 A KR20150168378 A KR 20150168378A KR 20170062781 A KR20170062781 A KR 20170062781A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- extract
- cognitive function
- weight
- parts
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000003920 cognitive function Effects 0.000 title claims abstract description 24
- 235000020710 ginseng extract Nutrition 0.000 title claims abstract description 11
- 230000000694 effects Effects 0.000 title abstract description 26
- 235000008434 ginseng Nutrition 0.000 claims abstract description 45
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 44
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 44
- 206010012289 Dementia Diseases 0.000 claims abstract description 14
- 238000005406 washing Methods 0.000 claims abstract description 6
- 241000208340 Araliaceae Species 0.000 claims abstract 5
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 239000000284 extract Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 4
- 240000006891 Artemisia vulgaris Species 0.000 claims 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 235000013402 health food Nutrition 0.000 abstract description 3
- 240000004371 Panax ginseng Species 0.000 description 40
- 230000000052 comparative effect Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 241000411851 herbal medicine Species 0.000 description 10
- 229940079593 drug Drugs 0.000 description 8
- 238000001035 drying Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 5
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 5
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 5
- 235000002789 Panax ginseng Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 5
- 229960002646 scopolamine Drugs 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 244000269722 Thea sinensis Species 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical group CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 4
- 229960004373 acetylcholine Drugs 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 244000018764 Nyssa sylvatica Species 0.000 description 3
- 235000003339 Nyssa sylvatica Nutrition 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000184734 Pyrus japonica Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 229960003980 galantamine Drugs 0.000 description 2
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
- 235000009569 green tea Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 description 2
- 230000008897 memory decline Effects 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 235000004936 Bromus mango Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 235000014826 Mangifera indica Nutrition 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 235000009184 Spondias indica Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000002363 herbicidal effect Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/882—Acoraceae (Calamus family), e.g. sweetflag or Acorus calamus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a composition containing a black ginseng extract having excellent cognitive function improving effect which can be used as a pharmaceutical composition for preventing and treating dementia and having excellent cognitive function improving effect or can be used as a health food composition having a cognitive function improving effect, More specifically, after washing of fresh ginseng, it is preheated in a humid heat at 55 to 70 ° C for 45 minutes to 300 minutes, then steamed at 75 to 85 ° C and dried at 50 to 80 ° C for 2 to 9 times, Or a pharmaceutically acceptable salt thereof.
Description
The present invention relates to a composition containing a black ginseng extract having excellent cognitive function improving effect, which can be used as a pharmaceutical composition for preventing and treating dementia, having excellent cognitive function improving effect, or as a health food composition having a cognitive function improving effect.
Dementia (dementia) is a common age-related disease in Korea, which is present in about 8.2 ~ 10.8% of the elderly population aged 65 and over and is rapidly becoming a serious social problem with rapid population aging. It is a degenerative disease that shows clinical signs of progressive devastation of personality. In recent years, digital dementia, in which not only senile dementia but also cognitive functions such as memory and calculation ability are greatly reduced by relying on various digital devices such as mobile phones, PDAs, and computers, is also common in young people.
Treatment with dementia by medication is mainly used as an anti-cholinesterase inhibitor, such as tacrine or aricept, which inhibits the decomposition of acetylcholine in the brain and maintains the concentration of acetylcholine at a certain level. These drugs have been recognized to some extent, but the long-term administration of high doses has been pointed out as a serious side effect of muscle pain, nausea due to gastrointestinal disorders, vomiting, diarrhea and anorexia as well as liver toxicity. An alternative method of promoting the synthesis of acetylcholine by administering an acetylcholine precursor such as choline was suggested. However, these substances do not pass through the cerebral blood vessel barrier, which is not effective enough. There is a growing interest in herbal medicines for safe prevention and treatment without side effects.
Ginseng (Panax ginseng CAMeyer), which has been said to be the flourishing agent of fire, bamboo, wax, and light, has excellent effect in prevention and treatment of various diseases, and it is a tonic agent that gives strength and vitality to people who have no disease at all. Lt; / RTI > It is said that there is no side effect even if it is used for a long time, and it is considered to be one of the best medicines among herbal medicine.
Ginseng, which is a ginseng in the field, contains about 70% of water, so it is susceptible to damage during storage or distribution. Red ginseng is obtained by steaming ginseng with steam and drying it. Black ginseng is a peculiar form of red ginseng, and it is produced by the corrugated gusset method, which is usually made nine times, unlike ordinary red ginseng, which is manufactured through a single boiling and drying process. The Enforcement Regulations of the Ginseng Industrial Act, amended in January 2012, distinguishes black ginseng from red ginseng and states that "black ginseng is steamed or steamed by steam or other methods and is dried and dark yellowish brown or blackish brown. According to the manufacturing standards, And the drying process is repeated three or more times. " The black ginseng is not only improved in storage stability but also has a unique pharmacological effect due to the formation of the saponin specific to black ginseng which is not present in the ginseng due to the chemical change of the active ingredient through heating and hydrolysis.
It has been reported that black ginseng is also effective in improving cognitive function and thus can be useful for prevention and treatment of dementia (Patent No. 10-1167628). However, black ginseng causes about 40% of body crack due to the volume expansion of ginseng and the starch swelling power due to the increase of the temperature inside ginseng. It is obvious that cracks in the shell can lead to the loss of the active ingredient as well as a drop in the product value due to the defective shape, as well as a leakage of the extract. In addition, since the distribution of saponin produced according to the conditions of green tea and the extraction is different from that of black ginseng, the active ingredient changes in the green tea ginseng process. Therefore, even if the cognitive function improving effect is known, .
Accordingly, it is an object of the present invention to provide a composition that can be used as a pharmaceutical composition for preventing and treating dementia, or as a health food composition having cognitive function improving effect, containing a black ginseng extract having excellent cognitive function improving effect.
In order to accomplish the above object, the present invention provides a method for preparing a ginseng extract, which comprises washing ginseng with ginseng, preheating the ginseng at a temperature of 55 to 70 ° C for 45 minutes to 300 minutes and then repeating the process of drying at 75 to 85 ° C and drying at 50 to 80 ° C for 3 to 9 times The present invention also relates to a pharmaceutical composition for preventing or treating dementia.
According to the preliminary experiment described in the patent application 10-2015-0052188 filed by the present inventors and not yet disclosed, it is possible to reduce the crack of the body during the steam process by preheating at 55 to 70 ° C with the wet heat before the black ginseng, We could also reduce losses due to the outflow of X. If the preheating temperature is too low, there is no effect of preheating. If the preheating temperature is over 70 ° C, the preheating temperature is too high, so that the cracking of the body may occur during the preheating process. Also, if the preheating time was less than 45 minutes, the effect of preheating was not sufficient. Even if the preheating time exceeded 300 minutes, the effect of preheating was not increased any more.
In addition, it is preferable that the blackening process is performed at 75 to 85 ° C. in the production of black ginseng. When the temperature is lower than 75 ℃, the browning is not accelerated. When the temperature is higher than 85 ℃, the sour taste and bitter taste are produced. In addition, the higher the temperature of the roasted tea, the greater the cracking of the shell, and the greater the yield of the soluble extract. This elution of the soluble extract is expected to lead to the loss of the active ingredient and also to the efficacy of the black ginseng, as confirmed in the following examples. That is, the extract of black ginseng produced by the method of the present invention is superior to the black ginseng prepared by the conventional method in that it is more effective in restoring the damage in the cognitive function damage model mouse, and is more effectively used for prevention and treatment of dementia Respectively.
The composition of the present invention may further be extracted by further mixing white ginseng with white ginseng so as to further enhance the cognitive function improving effect. It is known that Seokchangpo, Jeonji, and Baekbokrung have the effect of improving the cognitive function as raw materials of Sungmyunggang, which is described in Donguibogam. Although the concrete results are not described in the following examples, continuous research results of the present inventors have shown that the composition containing black ginseng added to black mushroom exerts excellent cognitive ability improving effect than that of black mushroom or black ginseng itself. This means that the combination of raw material of black mango and black ginseng shows a synergistic effect on improvement of cognitive ability.
Further, the composition of the present invention can be extracted by further containing arnia japonica. The compositions of Comparative Examples 1-2 and 1-2 containing rhizoglypsus were remarkably effective in improving the cognitive ability when compared with the compositions of Comparative Examples 1-1 and 1-1 that did not contain arninus japonica. In particular, the composition of Comparative Example 1-2 using black gum prepared by the prior art showed a stop-though latency of 83% and a distance-though latency of 74%, compared with Comparative Example 1-1, 2 had a stop-though latency of 73% and a distance-though latency of 59% when compared with that of Production Example 1-1, and thus it was confirmed that the addition of arginine was more effective in the composition using the black gum of the present invention there was.
The pharmaceutical composition may be formulated into powders, granules, tablets, capsules, injections, or the like in combination with a carrier generally accepted in the pharmaceutical field. The pharmaceutical composition according to the present invention can be administered in a pharmaceutically effective amount. The term "pharmaceutically effective amount" as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment. The effective dose level will depend on factors such as the type of disease, severity, age, drug activity, drug sensitivity, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent drugs, Can be determined accordingly. The composition of the present invention may be administered alone or in combination with other therapeutic agents, sequentially or concurrently with conventional therapeutic agents. The composition of the present invention is a herbal medicine which has been used for a long time in herbal medicine and has been proved to be non-toxic by long-term clinical tests. Therefore, , Which may be easily determined by those skilled in the art.
In addition, the present invention provides a food composition for improving cognitive function, which comprises a black ginseng extract used in the pharmaceutical composition for preventing or treating dementia. The black ginseng extract may be added to the composition of the present invention in an amount of preferably 0.01 to 100% by weight. The food composition of the present invention includes forms such as tablets, capsules, pills, and liquids. Examples of foods to which the composition of the present invention can be added include various foods, beverages, gums, tea, And health functional foods.
As described above, it was confirmed that the composition containing the black ginseng extract of the present invention is excellent in the effect of improving cognitive function of mice, and thus can be effectively used for prevention and treatment of dementia.
In addition, the composition of the present invention can be added to various foods to be used as a food composition capable of exhibiting a cognitive function improving effect not only for dementia patients but also for examinees and workers.
FIG. 1 is a graph showing the results of evaluating the ability of the extract of the present invention to improve cognitive function by stop-through latency in the test.
FIG. 2 is a graph showing the results of evaluating the ability of the extract of the present invention to improve the cognitive function by stop-through latency in the Sumi test.
FIG. 3 is an image showing a small amount of momentum (Smldist) and a lot of momentum (Lardist) in the test.
Hereinafter, the present invention will be described in more detail with reference to the accompanying preliminary experiments and examples. However, the drawings and the embodiments are only illustrative of the contents and scope of the technical idea of the present invention, and the technical scope of the present invention is not limited or changed. It will be apparent to those skilled in the art that various changes and modifications can be made within the scope of the technical idea of the present invention based on these examples.
Example 1: Preparation of black ginseng
Manufacturing Example: Preparation of Black Ginseng
Four years old ginseng was purchased at the market of Ginsan ginseng in early October and washed, and then preheated at 60 ° C for 45 minutes with moist heat and then boiled at 80 ° C for 7 hours. Then, it was dried for 8 hours at 80 ° C for 7 hours and then dried at 60 ° C for 2 hours and dried at 60 ° C for 24 hours to prepare black ginseng.
Comparative Example: Production of black gins by a conventional method without pretreatment
The same procedure as in the preparation example was followed, and the washed ginseng was subjected to heat treatment at 98 ° C for 7 hours. After that, drying at 60 ° C for 2 hours and drying at 98 ° C for 7 hours were repeated 8 times and dried at 60 ° C for 24 hours to prepare black gins by a conventional method.
Example 2: Preparation of crude drug extract
The herbal medicines listed in Table 1 below, including the black gins prepared in Example 1, were finely chopped and mixed according to the weight ratio shown in Table 1. Five times of distilled water was added to the total weight of the mixture, and the mixture was extracted twice at 90 DEG C for 5 hours, followed by filtration through a filter paper and washing. The filtrate and washing solution were combined, concentrated under reduced pressure and lyophilized to prepare herbal extract. In the following table, the examples show that black ginseng prepared according to the preparation example of the above-mentioned Example 1 and the comparative example are herbal medicine extracts prepared using the black gins produced according to the method of the comparative example of the above-mentioned Example 1. [
Example 3 Evaluation of the Improvement of Cognitive Function of Herbal Extracts by the Experimental Experiment
Seven-week-old C57bl / 6 mice were purchased from BioLink (Korea). The test animals were fed with standard diet (crude protein 22.1% or higher, crude fat 8.0% or less, crude fiber 5.0% or less, whey protein 8.0% or less, calcium 0.6% or more, phosphorus 0.4% or more, After being purified for 1 week in a laboratory environment, it was used in the experiment. After 1 week of refinement, mice with good health status were selected and repeated for 5 days once a day in Morris water maze for 1 week. Morris Sumilo was a water tank with a diameter of 90 cm and a height of 30 cm. It was made by filling a 2/3 tap water with a water temperature of 27 ° C, and installing a cylindrical platform with a diameter of 10 cm to which a mouse could climb. Once a day, ICR mice were selected from the pool to the platform within 30 seconds. Ten mice of the selected C57bl / 6 mice were divided into a control group and a positive control group (Galanthamine (3 mg / kg, ip ), herbal medicine group of each example and comparative example (200 mg / kg) In the control group, the herbal medicine extract of Table 1 was administered to the herbicide-treated group by intraperitoneal injection every day for one week by oral administration, and repeated training was performed on the platform three times a week.
After a total of 14 days of training and 7 days of drug administration, scopolamine (1 mg / kg) was intraperitoneally injected into C57bl / 6 mice of each experimental group 30 minutes later and C57bl / 6 mice One animal was placed, and the behavior was measured by VIDEOTRACK, which was analyzed by videotrack software. Results were recorded as mean ± standard error, and significance was tested at p <0.05 using Student's t-test.
1) Evaluation of inhibition of memory decline by stop-through latency
Figure 1 shows the results of stop-through latency analysis with videotracking 30 min after scopolamine administration. As shown in FIG. 1, in the 7-day repetition training, the mice that were within 30 seconds from the pool to the platform were treated with scopolamine after an additional 7 days of drug administration and repeated learning. As a result, After 30 minutes of scopolamine treatment, significant memory loss was noted at 43.5 seconds. The positive control group treated with the control drug Galanthamine had 14.5 seconds of inhibition of memory decline significantly compared with the control group. Herbal medicine extracts of Comparative Examples 1-1 and 1-2 showed 25.4 and 21.1 seconds, respectively, which were less effective than the positive control group, but showed remarkable inhibitory effect against the control group. Examples 1-1 and 1-2 using the black gums prepared in the preparation example prepared by pretreating with humid heat and boiled at a low temperature showed delay times of 19.8 and 14.5 seconds, respectively, and the compositions of Comparative Examples 1-1 and 1 -2, which is remarkable. This shows that the black ginseng prepared according to the preparation example of the present invention has an excellent effect for improving the cognitive function as compared with the conventional black ginseng according to the prior art.
2) Evaluation of the effect of inhibition of memory decay by distance movement-through latency
FIG. 2 shows movement distances moving in the pool until the repeatedly learned mice climb from the pool to the platform. FIG. 3 shows the movement amount as a threshold, which is a small movement (Smldist) and a large movement (Lardist) .
As can be seen in FIG. 2, the total exercise distance for the control mice to move from the pool to the platform was 911.8 cm, whereas the positive control group showed a significant decrease in the exercise amount by 333.7. Similar to the results of the stop-through latency measurement of 1), the herbal medicine extract of Comparative Example also showed a decrease in the momentum as compared with the control group, so that the exercise distance of 722.3 and 531.5 were measured in Comparative Examples 1-1 and 1-2, respectively, The reduction was not effective. On the other hand, in Examples 1-1 and 1-2, in which the composition containing the black gum prepared by the method of the present invention was administered, the exercise distances of 453.4 and 258.3 were measured, respectively, And showed similar or more significant effects compared with the positive control group.
FIG. 3 shows the interval between the small amount of exercise (Smldist) and the lot of exercise (Lardist) among the total amount of movement of the mouse in the water tank. ) Is decreased. This suggests that there is a correlation between scopolamine-induced memory loss and exercise.
Claims (6)
Wherein the extract is obtained by further mixing 80-120 parts by weight of Seokchonpo, 80-120 parts by weight of raw paper, and 80-120 parts by weight of Baekbokryeong with 100 parts by weight of black ginseng.
Wherein the extract is further extracted and mixed with 30 to 60 parts by weight of rhizome.
Wherein the extract is prepared by further mixing 80-120 parts by weight of Seokchonpo, 80-120 parts by weight of raw paper, and 80-120 parts by weight of Baekbokryeong with 100 parts by weight of black ginseng.
Wherein the extract is obtained by further mixing 30 to 60 parts by weight of horse mugwort.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150168378A KR20170062781A (en) | 2015-11-30 | 2015-11-30 | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150168378A KR20170062781A (en) | 2015-11-30 | 2015-11-30 | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20170062781A true KR20170062781A (en) | 2017-06-08 |
Family
ID=59220938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150168378A KR20170062781A (en) | 2015-11-30 | 2015-11-30 | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20170062781A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102018207167A1 (en) | 2017-05-22 | 2019-01-17 | Mando Corporation | STEERING DEVICE FOR A VEHICLE |
| KR20210079893A (en) * | 2019-12-20 | 2021-06-30 | 재단법인 금산인삼약초산업진흥원 | Black ginseng extract for improvement of cognitive ability and manufacturing method thereof |
| KR102295116B1 (en) * | 2020-10-23 | 2021-08-31 | 주식회사 한빛향료 | Manufacturing method of black ginseng to improve cognitive function and black ginseng manufactured by the method |
-
2015
- 2015-11-30 KR KR1020150168378A patent/KR20170062781A/en not_active Application Discontinuation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102018207167A1 (en) | 2017-05-22 | 2019-01-17 | Mando Corporation | STEERING DEVICE FOR A VEHICLE |
| KR20210079893A (en) * | 2019-12-20 | 2021-06-30 | 재단법인 금산인삼약초산업진흥원 | Black ginseng extract for improvement of cognitive ability and manufacturing method thereof |
| KR102295116B1 (en) * | 2020-10-23 | 2021-08-31 | 주식회사 한빛향료 | Manufacturing method of black ginseng to improve cognitive function and black ginseng manufactured by the method |
| WO2022086267A1 (en) * | 2020-10-23 | 2022-04-28 | 주식회사 한빛향료 | Method for preparation of black ginseng for improving cognitive function and black ginseng prepared by same method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101667952B1 (en) | Plant extract compositions for affecting sleep | |
| EP2117560B1 (en) | A composition for selective serotonin reuptake inhibition and process thereof | |
| KR101691205B1 (en) | Composition comprising herbal extract for preventing or treating fatty liver disease | |
| KR20190014376A (en) | Composition Comprising Sturgeon Extracts | |
| US20220226413A1 (en) | Traditional chinese medicine composition with improving cognition effect, preparation method thereof and traditional chinese medicine preparation | |
| KR20170062781A (en) | Composition Comprising Black Ginseng Extract having Improving Activity of Cognitive Function | |
| JP2020518596A (en) | Chinese herbal medicine extract effective for depression, its preparation method and use | |
| CN106036898A (en) | Composition having anti-fatigue effects and preparation method and use thereof | |
| KR20100091206A (en) | Pharmaceutical compositions with a mechanism of multi-target receptor retroaction for treating depression | |
| CN104739960B (en) | Stomach antibacterial combination, the stomach antibacterials containing said composition and preparation | |
| KR101354370B1 (en) | A composition for improving ability of memory or concentration | |
| CN110772564A (en) | Traditional Chinese medicine extract composition with depression mood regulating effect, preparation method thereof and traditional Chinese medicine preparation | |
| CN113813310B (en) | Traditional Chinese medicine composition for preventing and treating brain diseases and preparation method and application thereof | |
| KR101167628B1 (en) | A composition comprising black ginseng for treating or preventing dementia and improving cognitive function | |
| RU2671566C2 (en) | Pharmaceutical composition for preventing and treating senile dementia and preparation method therefor | |
| KR102038644B1 (en) | A pharmaceutical composition comprising tetragonia tetragonoides extract for preventing or treating depression | |
| CN104873842A (en) | Traditional Chinese medicine composition for treating infantile diarrhea | |
| KR20100092824A (en) | Pharmaceutical composition comprising chlorogenic acid or its salt as effective ingredient for preventing or treating of learning or memory disorder, or dementia | |
| CN101518642B (en) | Oral liquid preparations | |
| KR20190041776A (en) | Health tea composition and health tea using medicinal herbs | |
| KR101894540B1 (en) | Composition for improving coenzyme Q10 with extract of Pinellia ternata, Atractylodes macrocephala, Gastrodia elata, Citrus unshiu peel, Poria cocos, Crataegus pinnatifida, Siegesbeckia pubescens Makino and Coptis japonica Makino | |
| CN110302352A (en) | A kind of olive granule and preparation method thereof | |
| KR102052081B1 (en) | The composition for preventing and treating hepatitis B | |
| KR102036357B1 (en) | A pharmaceutical composition comprising lespedeza cuneata extract for preventing or treating depression | |
| KR101914738B1 (en) | Composition for Preventing or Improving Dementia Comprising a Dried Flower Bud Powder and Root of Black Panax Ginseng |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |